These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30684345)

  • 1. [New antidiabetic drugs: current status and future prospects - a review of the literature].
    Baranowska A; Stefanowicz-Rutkowska M; Matuszewski W; Bandurska-Stankiewicz E
    Wiad Lek; 2018; 71(8):1588-1598. PubMed ID: 30684345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular effects of antidiabetic drugs.
    Sørensen AM; Christensen MB
    Drugs Today (Barc); 2018 Sep; 54(9):547-559. PubMed ID: 30303495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiometabolic Effects of a New Class of Antidiabetic Agents.
    Desouza CV; Gupta N; Patel A
    Clin Ther; 2015 Jun; 37(6):1178-94. PubMed ID: 25754876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (7) Approaches to glycemic treatment.
    American Diabetes Association
    Diabetes Care; 2015 Jan; 38 Suppl():S41-8. PubMed ID: 25537707
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.
    Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L
    Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [GLP-1 receptor agonists versus SGLT-2 inhibitors in obese type 2 diabetes patients].
    Marques AR; Jaafar J; de Kalbermatten B; Philippe J
    Rev Med Suisse; 2015 Jun; 11(477):1227-8, 1230-3. PubMed ID: 26211282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of anti-diabetic therapy on overweight/obesity and dyslipidemia: traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors].
    Fiorentino TV; Sesti G
    G Ital Cardiol (Rome); 2013 Dec; 14(12 Suppl):15-25. PubMed ID: 24362783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New oral hypoglycemic drugs in diabetic kidney disease].
    Dylewska M; Graczyk M
    Wiad Lek; 2017; 70(6 pt 2):1193-1196. PubMed ID: 29533912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.
    DeFilippis EM; Givertz MM
    Curr Heart Fail Rep; 2016 Jun; 13(3):111-8. PubMed ID: 27188181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
    Ferrannini E; DeFronzo RA
    Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
    Madsbad S; Krarup T; Deacon CF; Holst JJ
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):491-9. PubMed ID: 18542012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drugs affecting the incretin system and renal glucose transport: do they meet the expectations of modern therapy of type 2 diabetes?].
    Gumieniczek A
    Postepy Hig Med Dosw (Online); 2016 May; 70():425-34. PubMed ID: 27180961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.
    Yassin SA; Aroda VR
    Drug Des Devel Ther; 2017; 11():923-937. PubMed ID: 28356718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs.
    Zhao Y; Yang L; Zhou Z
    J Diabetes; 2014 Jan; 6(1):21-9. PubMed ID: 23683065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review on the Effects of New Anti-Diabetic Drugs on Platelet Function.
    Yaribeygi H; Atkin SL; Jamialahmadi T; Sahebkar A
    Endocr Metab Immune Disord Drug Targets; 2020; 20(3):328-334. PubMed ID: 31612835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes.
    Deacon CF
    Peptides; 2018 Feb; 100():150-157. PubMed ID: 29412814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of Type 2 Diabetes: a Practical Approach].
    Donath M
    Praxis (Bern 1994); 2016 Jun; 105(12):699-702. PubMed ID: 27269776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug treatment of type 2 diabetes].
    Tielmans A; Laloi-Michelin M; Coupaye M; Virally M; Meas T; Guillausseau PJ
    Presse Med; 2007 Feb; 36(2 Pt 2):269-78. PubMed ID: 17258675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.